Biotech Daily Home

Biotech Daily covers the major announcements from ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Subscriptions are $A940 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

The website is best viewed with the Firefox browser.

Download subscription form here



Latest News !


Biotech Daily Policy On Mega-Day-Traders - May 3, 2016

Budget 2016: Not Much For Biotech, Innovation
- Details, Comment - May 3, 4, 2016

NHMRC $3.3m For Windfarm Health Impacts
AMA Position, Biotech Daily Comment - Mar 22, 2016

2015 - The Year In Review

PM Malcolm Turbull Launches $1.1b Innovation, Science Agenda
Comment - Dec 7, 8, 2015

Novartis Buys Spinifex For $916m

Genetic Technologies Dr Mervyn Jacobson 12 Months Gaol

Gaol For The Phosphagenics Three: Dr Esra Ogru
Dr Robert Gianello, Dr Woei-Jia Jiang

BRIL Group Senate Innovation Submission:
Set Aside 25% Of $20bn MRFF For Commercialization


April BDI-40 Up 1%
ASX200 Up 3%, Big Caps Up 2.5%

Tissue Therapies Up 57%, Prana 32%; Neuren Down 28%, Airxpanders 22%

Pro Medicus promoted into BDI-20

May 2, 2016
The Biotech Daily Top 40 Index (BDI-40) rose 1.3 percent in April to a collective market capitalization of $7,431 million, while the S&P ASX200 was up 3.3 percent for the month.
For the year to April 30, 2016, the BDI-40 (which does not include the three Big Caps of Cochlear, CSL and Resmed) climbed 30.8 percent while the ASX200 fell 9.3 percent.
All three Big Caps resumed their upward run after last month’s fall, recovering 2.5 percent and up 10.5 percent for the year to April 30. Cochlear climbed 5.6 percent to $6,180 million, CSL rose 2.6 percent to $48,163 million, with Resmed up 0.4 percent.
Twenty-three of the BDI-40 companies were up, 16 fell and one was unchanged, with 15 companies up more than 10 percent and six down more than 10 percent.
While Tissue Therapies was the best from a low base, up $8 million or 57.1 percent to $22 million, Pro Medicus continued to shine, up $94 million or 27.2 percent to $440 million and up 151.4 percent from 12 months ago. Prana recovered 32.4 percent to $45 million, followed by Avita (28.6%), Medical Developments (19.1%), Cellmid (18.75%), Orthocell (17.4%), Actinogen (17.1%), Psivida (15.7%), Viralytics (14.9%) and Anteo (12.7%).
Neuren led the falls on a second traumatic brain injury trial failure, down $52 million or 27.5 percent to $137 million, followed by Airxpanders contracting 22.0 percent, Admedus (20.6%), Universal Biosensors (18.75%), Mesoblast (14.9%) and Oncosil (12.5%).
The Nasdaq Biotech Index was up 2.9 percent in April, with former Australian companies Heartware up 7.0 percent to $769 million, Aviragen (Biota) up 6.6 percent to $81 million, and Sunshine Heart down a further $3 million or 15.0 percent to $17 million.
Outside the BDI-40, Phosphagenics soared 209.0 percent on its unnamed Japanese company deal, Innate leapt 48.6 percent on completing trial recruitment, Cyclopharm continued its steady rise, with Dorsavi, Cogstate and LBT showing stable growth.
Several companies are potentially worthy of promotion to the BDI-40, but for the time being the apparently unstoppable Pro Medicus will replace Benitec in the Top 20.
BDI-40 v S&P ASX200 Jun 30, 2006 to Apr 30, 2016 – Adjusted
BDI-40 v S&P ASX200 Apr 30, 2015 to Apr 30, 2016 
Big Caps (Cochlear, CSL, Resmed) Apr 30, 2015 to Apr 30, 2016


 Click here for Biotech Daily's archive



Biotech Daily Top 40 With Market Capitalization At Apr 30, 2016



* Biotech Daily editor, David Langsam, owns shares in Acrux, Admedus, Benitec, Mesoblast
   Nanosonics, Neuren and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: